Prestige Consumer Healthcare Inc.(PBH) Stock Research - Grey Stern Research
Loading...

Prestige Consumer Healthcare Inc. (PBH) Stock Analysis

$73.68 (-0.59%)

PBH Financial Performance


Use the table below to view Prestige Consumer Healthcare Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q1 - 2025

Metric Value Ranking among Peers
Price $72.91 -
52 Week Low $56.34 -
52 Week High $75.80 -
Market Cap $3.6 Billion 1/10
Gross Margin 53% 7/10
Profit Margin 18% 3/10
EBITDA margin 30% 4/10
Q1 - 2025 Revenue $267.1 Million 2/10
Q1 - 2025 Earnings $49.1 Million 1/10
Q1 - 2025 Free Cash Flow $53.6 Million 3/10
Trailing 4 Quarters Revenue $1.1 Billion 1/10
Trailing 4 Quarters Earnings $205.1 Million 1/10
Quarterly Earnings Growth -8% 7/10
Annual Earnings Growth 131% 5/10
Quarterly Revenue Growth -4% 9/10
Annual Revenue Growth -2% 9/10
Cash On Hand $34.3 Million 8/10
Short Term Debt $4.4 Million 5/10
Long Term Debt $1.1 Billion 1/10

Prestige Consumer Healthcare Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Prestige Consumer Healthcare Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 17.61 4/10
PS 3.25 4/10
PB 2.15 6/10
PC 105.48 1/10
Liabilities to Equity 0.97 5/10
ROA 0.06 3/10
ROE 0.12 3/10
Current Ratio 2.03 5/10
Quick Ratio 0.02 9/10
Long Term Debt to Equity 0.65 6/10
Debt to Equity 0.66 6/10
Burn Rate -7.95 7/10
Cash to Cap 0.01 10/10
CCR 1.09 7/10
EV to EBITDA 58.40 2/10
EV to Revenue 4.21 3/10

Company Details

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

CEO: Mr. Ronald Lombardi

Website: https://www.prestigebrands.com

Address: 660 White Plains Rd Tarrytown, NEW YORK

Exchange: New York Stock Exchange

Industry: Medical Distribution

Prestige Consumer Healthcare Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Prestige Consumer Healthcare Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Pacira BioSciences, Inc. PCRX $604.7 Million
Supernus Pharmaceuticals, Inc. SUPN $1.7 Billion
Collegium Pharmaceutical, Inc. COLL $1.2 Billion
Eagle Pharmaceuticals, Inc. EGRX $56.0 Million
ANI Pharmaceuticals, Inc. ANIP $1.2 Billion
Amphastar Pharmaceuticals, Inc. AMPH $2.3 Billion
Phibro Animal Health Corporation PAHC $890.7 Million
Deciphera Pharmaceuticals, Inc. DCPH $2.2 Billion
Silver Spike Investment Corp. SSIC $70.7 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
PBH Income Statements
Quarter Year Revenue Earnings
Q1 2025 $ 267.1 Million $49.1 Million
Q4 2024 $ 277.0 Million $49.5 Million
Q3 2024 $ 282.7 Million $53.0 Million
Q2 2024 $ 286.3 Million $53.6 Million
Q1 2024 $ 279.3 Million $53.3 Million
Q4 2023 $ 285.9 Million -$240.6 Million
Q3 2023 $ 275.5 Million $52.0 Million
Q2 2023 $ 289.3 Million $51.0 Million

View All

PBH Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q1 2025 $34.3 Million $3.3 Billion $1.1 Billion $1.7 Billion
Q4 2024 $46.5 Million $3.3 Billion $1.1 Billion $1.7 Billion
Q3 2024 $63.6 Million $3.3 Billion $1.2 Billion $1.6 Billion
Q2 2024 $60.1 Million $3.3 Billion $1.3 Billion $1.5 Billion
Q1 2024 $54.6 Million $3.3 Billion $1.3 Billion $1.5 Billion
Q4 2023 $58.5 Million $3.4 Billion $1.4 Billion $1.4 Billion
Q3 2023 $86.4 Million $3.7 Billion $1.4 Billion $1.7 Billion
Q2 2023 $42.4 Million $3.7 Billion $1.5 Billion $1.6 Billion

View All

PBH Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q1 2025 $53.6 Million -$1.2 Million -$12.2 Million
Q4 2024 $63.8 Million -$3.1 Million -$17.1 Million
Q3 2024 $69.5 Million -$2.0 Million $3.5 Million
Q2 2024 $59.5 Million -$2.9 Million $5.5 Million
Q1 2024 $46.6 Million -$1.5 Million -$3.9 Million
Q4 2023 $56.4 Million -$2.6 Million -$27.9 Million
Q3 2023 $53.1 Million -$1.8 Million $43.9 Million
Q2 2023 $55.2 Million -$2.4 Million $6.6 Million

View All